Literature DB >> 29464501

A Systematic Review of Probiotic Interventions for Gastrointestinal Symptoms and Irritable Bowel Syndrome in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME).

Matthew Corbitt1, N Campagnolo2,3, D Staines2,3, S Marshall-Gradisnik2,3.   

Abstract

Gastrointestinal (GI) symptoms and irritable bowel (IB) symptoms have been associated with chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME). The aim of this study was to conduct a systematic review of these symptoms in CFS/ME, along with any evidence for probiotics as treatment. Pubmed, Scopus, Medline (EBSCOHost) and EMBASE databases were searched to source relevant studies for CFS/ME. The review included any studies examining GI symptoms, irritable bowel syndrome (IBS) and/or probiotic use. Studies were required to report criteria for CFS/ME and study design, intervention and outcome measures. Quality assessment was also completed to summarise the level of evidence available. A total of 3381 publications were returned using our search terms. Twenty-five studies were included in the review. Randomised control trials were the predominant study type (n = 24). Most of the studies identified examined the effect of probiotic supplementation on the improvement of IB symptoms in IBS patients, or IB symptoms in CFS/ME patients, as well as some other significant secondary outcomes (e.g. quality of life, other gastrointestinal symptoms, psychological symptoms). The level of evidence identified for the use of probiotics in IBS was excellent in quality; however, the evidence available for the use of probiotic interventions in CFS/ME was poor and limited. There is currently insufficient evidence for the use of probiotics in CFS/ME patients, despite probiotic interventions being useful in IBS. The studies pertaining to probiotic interventions in CFS/ME patients were limited and of poor quality overall. Standardisation of protocols and methodology in these studies is required.

Entities:  

Keywords:  Chronic fatigue syndrome; Gastrointestinal symptoms; Irritable bowel symptoms; Myalgic encephalomyelitis; Probiotics

Mesh:

Year:  2018        PMID: 29464501     DOI: 10.1007/s12602-018-9397-8

Source DB:  PubMed          Journal:  Probiotics Antimicrob Proteins        ISSN: 1867-1306            Impact factor:   4.609


  52 in total

1.  Rome IV-Functional GI Disorders: Disorders of Gut-Brain Interaction.

Authors:  Douglas A Drossman; William L Hasler
Journal:  Gastroenterology       Date:  2016-05       Impact factor: 22.682

2.  Effects of 12 weeks of probiotic supplementation on quality of life in colorectal cancer survivors: a double-blind, randomized, placebo-controlled trial.

Authors:  Jee-Yon Lee; Sang-Hui Chu; Justin Y Jeon; Mi-Kyung Lee; Ji-Hye Park; Duk-Chul Lee; Ji-Won Lee; Nam-Kyu Kim
Journal:  Dig Liver Dis       Date:  2014-10-23       Impact factor: 4.088

3.  Therapeutic effects of oral NADH on the symptoms of patients with chronic fatigue syndrome.

Authors:  L M Forsyth; H G Preuss; A L MacDowell; L Chiazze; G D Birkmayer; J A Bellanti
Journal:  Ann Allergy Asthma Immunol       Date:  1999-02       Impact factor: 6.347

4.  Clinical trial: effect of active lactic acid bacteria on mucosal barrier function in patients with diarrhoea-predominant irritable bowel syndrome.

Authors:  J Zeng; Y-Q Li; X-L Zuo; Y-B Zhen; J Yang; C-H Liu
Journal:  Aliment Pharmacol Ther       Date:  2008-07-30       Impact factor: 8.171

5.  Cytokine and clinical response to Saccharomyces boulardii therapy in diarrhea-dominant irritable bowel syndrome: a randomized trial.

Authors:  Zaigham Abbas; Javed Yakoob; Wasim Jafri; Zubair Ahmad; Zahid Azam; Muhammad W Usman; Sara Shamim; Muhammad Islam
Journal:  Eur J Gastroenterol Hepatol       Date:  2014-06       Impact factor: 2.566

6.  The specificity of the CDC-1994 criteria for chronic fatigue syndrome: comparison of health status in three groups of patients who fulfill the criteria.

Authors:  Gwen Kennedy; Neil C Abbot; Vance Spence; Christine Underwood; Jill J F Belch
Journal:  Ann Epidemiol       Date:  2004-02       Impact factor: 3.797

7.  Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: a multicentre, randomized, double-blind, controlled trial.

Authors:  D Guyonnet; O Chassany; P Ducrotte; C Picard; M Mouret; C-H Mercier; C Matuchansky
Journal:  Aliment Pharmacol Ther       Date:  2007-08-01       Impact factor: 8.171

8.  Randomized controlled treatment trial of irritable bowel syndrome with a probiotic E.-coli preparation (DSM17252) compared to placebo.

Authors:  P Enck; K Zimmermann; G Menke; S Klosterhalfen
Journal:  Z Gastroenterol       Date:  2009-02-05       Impact factor: 2.000

9.  A double-blind placebo-controlled trial to study therapeutic effects of probiotic Escherichia coli Nissle 1917 in subgroups of patients with irritable bowel syndrome.

Authors:  Wolfgang Kruis; Sigrun Chrubasik; Stephan Boehm; Christiane Stange; Juergen Schulze
Journal:  Int J Colorectal Dis       Date:  2011-12-02       Impact factor: 2.571

Review 10.  Dietary and nutrition interventions for the therapeutic treatment of chronic fatigue syndrome/myalgic encephalomyelitis: a systematic review.

Authors:  N Campagnolo; S Johnston; A Collatz; D Staines; S Marshall-Gradisnik
Journal:  J Hum Nutr Diet       Date:  2017-01-22       Impact factor: 3.089

View more
  9 in total

1.  Effects of Probiotics on Inflammation and Uremic Toxins Among Patients on Dialysis: A Systematic Review and Meta-Analysis.

Authors:  Charat Thongprayoon; Wisit Kaewput; Spencer T Hatch; Tarun Bathini; Konika Sharma; Karn Wijarnpreecha; Patompong Ungprasert; Matthew D'Costa; Michael A Mao; Wisit Cheungpasitporn
Journal:  Dig Dis Sci       Date:  2018-08-11       Impact factor: 3.199

Review 2.  Are probiotics useful in the treatment of chronic idiopathic constipation in adults? A review of existing systematic reviews, meta-analyses, and recommendations.

Authors:  Mikołaj Kamiński; Karolina Skonieczna-Żydecka; Igor Łoniewski; Anastasios Koulaouzidis; Wojciech Marlicz
Journal:  Prz Gastroenterol       Date:  2019-07-17

Review 3.  Glial Activation and Expression of the Serotonin Transporter in Chronic Fatigue Syndrome.

Authors:  Mami Noda; Masataka Ifuku; Md Shamim Hossain; Toshihiko Katafuchi
Journal:  Front Psychiatry       Date:  2018-11-16       Impact factor: 4.157

4.  A systematic review of enteric dysbiosis in chronic fatigue syndrome/myalgic encephalomyelitis.

Authors:  S Du Preez; M Corbitt; H Cabanas; N Eaton; D Staines; S Marshall-Gradisnik
Journal:  Syst Rev       Date:  2018-12-20

Review 5.  Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Comprehensive Review.

Authors:  Mateo Cortes Rivera; Claudio Mastronardi; Claudia T Silva-Aldana; Mauricio Arcos-Burgos; Brett A Lidbury
Journal:  Diagnostics (Basel)       Date:  2019-08-07

Review 6.  Anti-Inflammatory Diets and Fatigue.

Authors:  Ulrike Haß; Catrin Herpich; Kristina Norman
Journal:  Nutrients       Date:  2019-09-30       Impact factor: 5.717

7.  A systematic review of cytokines in chronic fatigue syndrome/myalgic encephalomyelitis/systemic exertion intolerance disease (CFS/ME/SEID).

Authors:  Matthew Corbitt; Natalie Eaton-Fitch; Donald Staines; Hélène Cabanas; Sonya Marshall-Gradisnik
Journal:  BMC Neurol       Date:  2019-08-24       Impact factor: 2.474

Review 8.  Potential Implications of Mammalian Transient Receptor Potential Melastatin 7 in the Pathophysiology of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Review.

Authors:  Stanley Du Preez; Helene Cabanas; Donald Staines; Sonya Marshall-Gradisnik
Journal:  Int J Environ Res Public Health       Date:  2021-10-12       Impact factor: 3.390

Review 9.  The Gut Microbiome in Myalgic Encephalomyelitis (ME)/Chronic Fatigue Syndrome (CFS).

Authors:  Rahel S König; Werner C Albrich; Christian R Kahlert; Lina Samira Bahr; Ulrike Löber; Pietro Vernazza; Carmen Scheibenbogen; Sofia K Forslund
Journal:  Front Immunol       Date:  2022-01-03       Impact factor: 8.786

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.